Table 1 AVF survival rates according to clinical characteristics.
| Characteristic | Patients (n) | Three years n (%) | Five years n (%) | Median survival (range) (years) | P value |
|---|---|---|---|---|---|
| Overall | 290 | 148 (51.0) | 100 (34.5) | 3.1 (0.1–12.3) | |
| Age (years) | 0.001 | ||||
| <65 | 178 | 99 (55.6) | 77 (43.3) | 3.3 (0.1–12.3) | |
| 65–79 | 85 | 41 (48.2) | 20 (23.5) | 2.5 (0.1–7.8) | |
| ≥80 | 27 | 8 (29.6) | 3 (11.1) | 1.6 (0.3–7.8) | |
| Gender, n (%) | 0.317 | ||||
| Male | 142 | 75 (52.8) | 54 (38.0) | 3.1 (0.1–10.7) | |
| Female | 148 | 73 (49.3) | 46 (31.1) | 2.6 (0.1–12.3) | |
| Body mass index (kg/m2) | 0.971 | ||||
| <20 | 28 | 14 (50.0) | 8 (28.6) | 2.9 (0.1–7.4) | |
| 20.0–24.9 | 156 | 82 (52.6) | 54 (34.6) | 3.1 (0.1–12.3) | |
| 25.0–29.9 | 82 | 42 (51.2) | 29 (35.4) | 3.3 (0.3–10.7) | |
| ≥30.0 | 24 | 10 (41.7) | 9 (37.5) | 1.5 (0.3–6.3) | |
| DM, n (%) | 0.003 | ||||
| No | 146 | 87 (56.9) | 60 (41.1) | 3.4 (0.1–12.3) | |
| Yes | 144 | 61 (42.4) | 40 (27.8) | 1.8 (0.1–10.7) | |
| Not requiring insulin | 73 | 32 (43.8) | 24 (32.9) | 2.0 (0.3–7.6) | |
| Requiring insulin | 71 | 29 (40.8) | 16 (22.5) | 1.8 (0.1–10.7) | |
| Hypertension, n (%) | 0.918 | ||||
| No | 52 | 28 (53.8) | 18 (34.6) | 3.1 (0.1–12.3) | |
| Yes | 238 | 120 (50.4) | 82 (34.5) | 3.0 (0.1–10.7) | |
| IHD, n (%) | 0.007 | ||||
| No | 240 | 130 (54.2) | 91 (37.9) | 3.2 (0.1–12.3) | |
| Yes | 50 | 18 (36.0) | 9 (18.0) | 1.6 (0.3–7.2) | |
| Cerebrovascular disease, n (%) | 0.073 | ||||
| No | 271 | 143 (52.8) | 97 (35.8) | 3.2 (0.1–12.3) | |
| Yes | 19 | 5 (26.3) | 3 (15.8) | 1.8 (0.4–5.0) | |
| Cancer, n (%) | 0.283 | ||||
| No | 274 | 142 (51.8) | 97 (35.4) | 3.1 (0.1–12.3) | |
| Yes | 16 | 6 (37.5) | 3 (18.8) | 2.3 (0.3–5.5) | |
| Antithrombotic agents, n (%) | 0.115 | ||||
| No | 181 | 94 (51.9) | 69 (38.1) | 3.1 (0.1–12.3) | |
| Yes | 109 | 54 (49.5) | 31 (28.4) | 2.6 (0.3–7.2) | |
| Statins | 0.237 | ||||
| No | 164 | 81 (49.4) | 51 (31.1) | 2.5 (0.1–11.1) | |
| Yes | 126 | 67 (53.2) | 49 (38.9) | 3.1 (0.3–12.3) | |
| Calcium channel blockers, n (%) | 0.962 | ||||
| No | 107 | 56 (52.3) | 35 (32.7) | 3.2 (0.1–12.3) | |
| Yes | 183 | 92 (50.3) | 65 (35.5) | 3.0 (0.1–10.7) | |
| ACE inhibitors or ARBs, n (%) | 0.428 | ||||
| No | 230 | 114 (49.6) | 76 (33.0) | 2.8 (0.1–12.3) | |
| Yes | 60 | 34 (56.7) | 24 (40.0) | 3.3 (0.1–10.7) | |
| Beta blockers, n (%) | 0.099 | ||||
| No | 152 | 84 (55.3) | 59 (38.8) | 3.3 (0.1–12.3) | |
| Yes | 138 | 64 (46.4) | 41 (29.7) | 2.2 (0.1–7.8) | |
| Prior CVC placement, n (%) | <0.001 | ||||
| No | 158 | 94 (59.5) | 75 (47.5) | 3.8 (0.1–10.7) | |
| Yes | 132 | 54 (40.9) | 25 (18.9) | 2.0 (0.1–12.3) | |
| Intervention before AVF maturation, n (%) | 0.939 | ||||
| No | 248 | 124 (50.0) | 88 (35.5) | 2.9 (0.1–12.3) | |
| Yes | 42 | 24 (57.1) | 12 (28.6) | 3.3 (0.5–9.0) |
ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; AVF: arteriovenous fistula; CVC: central venous catheter; DM: diabetes mellitus; IHD: ischemic heart disease; n: number